The Clinical Research Of GDP Regimen On NK/T-cell Lymphoma

Objective: This study was aimed to evaluate efficacy and survivability of GDPregimen in the treatment of NK／T-cell lymphoma.Method: From May2008to December2013there are42cases in total taken byThe First Guangxi Hospital of University, that is decided as NK/T celllymphoma tumor case by pathological diagnosis. Patients are taken the GDPregimen (gemcitabine1000mg/m2on Day1and Day8,dexamethasone40mg/day on Day1to Day4, and daunorubicinum20-30mg/m2on Day1to Day3),every three weeks for one cycle, and it will be evaluated the efficacy in twoconsecutive cycles. The efficacy evaluation is measured using solid tumorevaluation criteria.42patients are analyzed by the indicators such asORR(overall response rate), CBR(clinical beneficial rate),OS(overall survival),the adverse effects rate and so on.Results:1. Short-term efficacy:Of42assessable patients24had response, including that17had completeresponse,7had partial response,11had stable disease, and7had progressive disease. The overall response rate was57.1%, the clinical beneficial rate was83.3%.2. Prognosis analysis:In the entire team the time of median survival is34months, the averagesurvival time is37.8months. The survival rate of1,2,5is78.1%、50,9%、40.5%respectively. The survival of5years for early stage (I and II phase) patients is49.3%respectively; the survival of5years for later stage(III and IV phase)patients are0%respectively; The factors impacting the prognosis include: theexistence of radiation therapy, LDH, the existence of CR after therapy。3.Adverse effects:The adverse effects of Chemotherapy toxicity was0-II digestive tract andbone marrow toxicity: the decreased incidence rates of leukocyte、hemoglobinand platelets were81.3%、56.3%and53.1%, the III/IV toxic incidence rates ofleukocyte、hemoglobin and platelets were21.9%、12.5%and9.3%; there wereobvious no heart and hepatorenal harm, no treatment-related death.Conclusion: there is certain curative effect for GDP regimen in NK/T celllymphoma patients,as well as poor toxicity.However, we need to expand thesample size and more strict Randomized controlled trials to prove its clinicalefficacy.